Fidelity Investments
DYN icon

Fidelity Investments’s Dyne Therapeutics DYN Stock Holding History

Fidelity Investments’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162M Buy
8,908,980
+2,339,059
+36% +$40.3M 0.01% 962
2025
Q4 		$129M Buy
6,569,921
+1,168,005
+22% +$22.1M 0.01% 1060
2025
Q3 		$68.3M Buy
5,401,916
+108,547
+2% +$1.24M ﹤0.01% 1329
2025
Q2 		$50.4M Buy
5,293,369
+98,075
+2% +$1.08M ﹤0.01% 1392
2025
Q1 		$54.3M Sell
5,195,294
-2,801,637
-35% -$40.1M ﹤0.01% 1325
2024
Q4 		$188M Sell
7,996,931
-1,029,766
-11% -$30.5M 0.01% 851
2024
Q3 		$324M Buy
9,026,697
+3,707,734
+70% +$148M 0.02% 638
2024
Q2 		$188M Buy
5,318,963
+2,100,570
+65% +$61M 0.01% 805
2024
Q1 		$91.4M Buy
3,218,393
+1,935,581
+151% +$43.8M 0.01% 1096
2023
Q4 		$17.1M Buy
1,282,812
+436,452
+52% +$4.26M ﹤0.01% 1680
2023
Q3 		$7.58M Sell
846,360
-52,932
-6% -$570K ﹤0.01% 1919
2023
Q2 		$10.1M Buy
899,292
+490,236
+120% +$5.78M ﹤0.01% 1858
2023
Q1 		$4.71M Sell
409,056
-165,064
-29% -$2.14M ﹤0.01% 2117
2022
Q4 		$6.65M Buy
574,120
+500,878
+684% +$5.8M ﹤0.01% 2034
2022
Q3 		$930K Buy
73,242
+409
+0.6% +$4.69K ﹤0.01% 2623
2022
Q2 		$500K Buy
72,833
+66
+0.1% +$455 ﹤0.01% 2846
2022
Q1 		$701K Buy
72,767
+55,567
+323% +$473K ﹤0.01% 2878
2021
Q4 		$205K Buy
+17,200
New +$242K ﹤0.01% 2953
2021
Q2 		– Sell
-211,483
Closed -$3.28M – 4387
2021
Q1 		$3.28M Buy
211,483
+93,883
+80% +$1.82M ﹤0.01% 2360
2020
Q4 		$2.47M Hold
117,600
– – ﹤0.01% 2361
2020
Q3 		$2.37M Buy
+117,600
New +$2.58M ﹤0.01% 2267

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments's DYN Position: Q1 2026 in Review

Fidelity Investments increased its Dyne Therapeutics (DYN) stake by 36% in Q1 2026, buying an estimated $40.3M and bringing the position to 8,908,980 shares worth $162M. The position accounts for 0.01% of the portfolio, ranked #962.

Fidelity Investments first reported a position in DYN in Q3 2020 and has held it in 21 quarters since. The position peaked at $324M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Fidelity Investments held 8,908,980 shares of Dyne Therapeutics worth $162M as of Q1 2026.
  • Fidelity Investments bought 2,339,059 Dyne Therapeutics shares in Q1 2026, an estimated $40.3M.
  • Dyne Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #962 holding.
  • Fidelity Investments first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Fidelity Investments's Dyne Therapeutics position peaked at $324M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.